Condition: Acute Hepatic Porphyria · Sponsor: Alnylam Pharmaceuticals
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
This description comes directly from the study's public registry record.
Alnylam Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Alnylam Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Birmingham, Alabama, United States | Recruiting |
| Clinical Trial Site | Gilbert, Arizona, United States | Recruiting |
| Clinical Trial Site | San Francisco, California, United States | Recruiting |
| Clinical Trial Site | Baltimore, Maryland, United States | Recruiting |
| Clinical Trial Site | Boston, Massachusetts, United States | Recruiting |
| Clinical Trial Site | Minneapolis, Minnesota, United States | Recruiting |
| Clinical Trial Site | New York, New York, United States | Recruiting |
| Clinical Trial Site | Winston-Salem, North Carolina, United States | Completed |
| Clinical Trial Site | Oklahoma City, Oklahoma, United States | Recruiting |
| Clinical Trial Site | Philadelphia, Pennsylvania, United States | Completed |
| Clinical Trial Site | Galveston, Texas, United States | Recruiting |
| Clinical Trial Site | Salt Lake City, Utah, United States | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04883905